Ichnos Sciences names new chief development officer
6 February 2020 -

It was reported on Wednesday, that Ichnos Sciences Inc, a fully integrated, global biotech, has named Gabriela Gruia, MD as its new chief development officer, effective immediately.

Dr Gruia will manage assets dealing with regulatory sciences, clinical operations, drug safety, clinical pharmacology, biostatistics and clinical outsourcing.

Dr Gruia has more than 20 years of oncology drug development and leadership experience in the pharmaceutical industry. She previously served as SVPt and head of Regulatory Affairs for Novartis Oncology, and designed and implemented an international strategy to develop a treatment for first- and second-line metastatic colorectal cancer at Pharmacia and Pfizer.